Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
Clinical trial NCT04091451 · COMPLETED
Trial details
- NCT number
- NCT04091451
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-17
- Primary completion
- 2024-02-15
- Enrollment
- 1430
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.